glp 1 generic drugs More people with type diabetes are using GLP-1 drugs, study finds, despite limited evidence on safety or effectiveness GLP-1 Drugs from the Gray

Previous reviews, while exploring the impact of GLP-1RAs on immune and inflammatory diseases, have not established a connection between the regulatory roles of immune cells and the impact of the treatment on disease progression

45 All studies that demonstrated a reduction in MACE on GLP-1RA therapy consistently involved patients with T2D

L., Fortin, S

GLP-1 may also affect systemic energy metabolism by stimulating thermogenesis in brown adipose tissue and browning of white adipose tissue [43]

April 18, 2026 Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs state regulators directed to enforce Medical Dialogues March 24, 2026 CDSCO tightens checks on generic semaglutide bans promotional activity, intensifies pharmacy surveillance Business Standard March 21, 2026 Patent expiry Day 1 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions CNBC March 17, 2026 ZydusLupin and ZydusTorrent licensing agreements announced ahead of patent expiry Pearce IP February 2026 Natco Pharma receives CDSCO approval for generic semaglutide Eris Lifesciences to commercialise Fierce Pharma December 2025 Sun Pharma receives first DCGI approval for generic semaglutide in India Noveltreat and Sematrinity Sun Pharma PR REGULATORY FRAMEWORK CDSCO Standards & Approval Requirements in India India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator equivalent to the US FDA

All authors approved the version to be published